“In recent months China’s progress in artificial intelligence has stunned the world. A quieter yet equally significant shift is under way in biotech. China has long been known for churning out generic drugs, supplying raw ingredients and managing clinical trials […]
Science reporter Charles Piller questions the pharmaceutical industry incentives in the fight against prediabetes. “A third of Americans are considered prediabetic—but many may be better off without treatment.” My take: I think he makes a good point about incentives but […]
“One of the uncomfortable truths about the pharmaceutical industry is that most approved drugs (~55%) don’t make enough money to recoup their development costs. The distribution of drug profits is “fat-tailed”, and the profits from a small fraction of drugs […]
“When it comes to CBD in food, considering CBD is an ingredient in FDA-approved pharmaceuticals, the FDA emphasized that ‘allowing drug ingredients in foods can undermine the drug approval process and diminish commercial incentives for further clinical study of the […]
Nisarg Patel writes an interesting post that discusses how healthcare is evolving as a tech-enabled consumer business. “A swath of chronic diseases desperately need integrated, end-to-end solutions that seamlessly integrates pharmaceuticals, software, and support services in a single package.”